Trousseau is generally credited with clinically et a1 4 and Falanga et al 5 and will not be discussed in this recognizing the connection between phlegmasia alba article. dolens and cancer.! However, the first to present sound As td the pathogenesis of thrombosis, the princi histological evidence for the presence of fibrin in tu ples put forth bv VirchoW' apply to the cancer patient as mors was Billroth. 1 Since then, much knowledge has well. Abnorm<llities in the blood How and changes in been gained as to the clinical picture, laboratory find the blood \'essels and in the contents of blood are all ings, and pathogenesis of thrombosis in malignant dis present in malignant diseases. There are additional fac eases. Abnormalities in the blood of cancer patients tors as a result of the contribution of tumor cells. ]Viost have been observed by many investigators, especially in of these changes are extensively reviewed elsewhere. 7 the levels of coagulation factors and in the fibrinolytic This article will be devoted to updating the role of system. 3 TF has been found in most cancer tissues. 13, 14 The high expression of TF may be a characteristic of the ma lignancy of a cell, as illustrated in the case of acute promyelocytic leukemia CAPL). The upregulated mes senger RNA (mRNA) of TF in the APL cell returns rapidly to normal levels upon the differentiation of the cell to normal neutrophils after treatment with ail-trans retinoic acid (ATRA).15
ACTIVATION OFTISSUE FACTOR DURING APOPTOSIS
Despite the rich content ofTF in tumor cells, it is dor mant. Activation will occur when the tumor undergoes apoptosis. In the nonapoptotic cell, the distribution of phospholipids is asymmetrical, and, as such, almost the entire PS molecule is sequestered in the inner leaflet of the plasma membrane. During apoptosis, PS exposure ("fup-flop" action) is an early event preceding DNA fragmentation, membrane blebbing, and loss of mem brane integrity. This process is believed to enable the activation ofTF and brings about its potent procoagu lant activity. This phenomenon of increased TF activity in apoptosis is illustrated in Figure 1 . A human APL cell line, NB4, was induced by camptothecin, a topoiso merase inhibitor. Increasing doses of camptothecin re sulted in progressive degrees of apoptosis. The TF activ- Apoptosis (%) . .
... g .. ity and the thrombin generated by these apoptotic cells were then measured. It can be seen that the amount of TF activity and the thrombin generated by these cells was directly proportional to the degree of apoptosis (p < 0_005 and < 0.0005, respectively). 16 Both TF activation and thrombin generation were also studied in a variety of apoptotic cells, both benign and malignant, including APL (NB4), human acute mveloid leukemia (HL60), Figure 2_ In all cases, a higher degree of apoptosis is accompanied by increasing TF activation and greater amounts of throm bin generated. These data support the concept that dur ing apoptosis, PS localized normally in the inner plasma membrane is exteriorized, resulting in the activation of TE Annexin V is a plasma protein with a high affinity for PS.1t binds and neutralizes the action ofPS. When added to apoptotic cells, annexin V was able to prevent the activation ofTF and of thrombin generation, sup porting the role of PS in the thrombogenicity of apop totic cells. Because apoptosis can be induced when the tumor cell is subjected to anoxia, chemotherapeutic agents, radiation, hormones, or hematopoietic growth factors, this finding is of obvious clinical significance.
Cancer Procoagulant CP is a cysteine proteinase that can directly activate F X in the absence of F VIIY It is expressed in embryonic (amniotic and chorionic cells) tissues and in many ma lignant cells and tissues including APL blasts. Because it is not found in normal, differentiated cells, its pres en.ce has been used to differentiate normal from ma lignant tissues. Using enzyme-linked immunosor bent assay (ELISA), CP has been used as a tumor marker. 18 ,19 CP antigen is present in the blood of cancer patients. However, when the CP activity was investi gated in the blood of breast cancer patients, it was found in the blood of patients with stages I and II but not in those with stages III and IV disease. The investigators believed that antibodies might have formed in those with advanced disease blocking the CP activity.2o If this finding of a lack of correlation between the tumor bur den and the CP activity were to be verified, then the significance of CP as a clinically relevant diagnostic test could be significantly attenuated. A compilation of both TF and CP activities in human and animal tumors was In a cancer patient, its inhibitory effect on thrombosis is believed to be overwhelmed when there is excessive apoptosis with TF activation.
Changes in the Fibrinolytic System
The presence of inhibitors of fibrinolysis was observed in cancer patients long before the plasminogen activator inhibitor type 1 (PAI-1) was identified. Many of the early studies centered on the clinical observations of in creased thrombosis in carcinoma of the pancreas and were based on global measurements of fibrinolysis, such as the euglobulin lysis time and fibrin plate lysis of eu globulin fractions of patients' blood. Subsequent studies employing more elaborate assays of plasminogen activa tors, 00 2 -antiplasmin, and PAl -1 revealed an overall pic ture of impaired fibrinolytic activity. The contribution of the tumor tissues in the inhibition of plasma fibrino lytic activity was also documented. Many of the studies were also confounded by the presence of disseminated intravascular coagulation (DIC) in the patients, result ing in the activation of secondary fibrinolysis. Thus, the presence of decreased fibrinolysis in cancer may not necessarily add to the thrombophilic state of this con dition, and its role in thrombogenesis is overshadowed by more recent findings that this system is involved in tumor growth and metastasis. 42 ,43 
CLINICAL IMPLICATIONS

Thromboembolic Event as First Manifestation of a Malignant Disease
If there is a strong procoagulant activity of tumor cells, under the appropriate conditions, even with a small tumor load, the effects may be that of a causative factor for a thromboembolic event. In Kwaan and coworkers'3 early observation in hepatocellular carcinoma, the plasma fibrinolytic activity was inhibited even when the tumor size was as small as 2 X 2 cm. This was explained on the basis of a high content of inhibitors of fibrinolysis in the tumor. A parallel example may be seen when procoagu lants are released by tumor cells that express high levels of TF, as in the case of API" A DIC picture is a conunon presentation even in early disease. Thus, this concept may be relevant in another clinical situation. In a patient pre senting with "idiopathic" thrombosis, without an appar ent precipitating cause, the underlying etiology of the thrombosis may be an occult cancer. In a prospective study by Heittiarachchi et 
The Combination of Multiple Risk Factors
In an individual cancer patient, susceptibility to throm bosis can be enhanced by the concurrence of other factors, including immobilization, dehydration, advanced age, smoking, diabetes, hypertension, nephrotic syndrome, inflammatory bowel disease, and prior to thromboem bolism. In a given form of cancer, multiple factors may be present, each contributing to the added risk of thrombo sis. This is well-exemplified in the case ofAPL and in car cinoma of the breast, both ofwhich have been extensively studied.
ACUTE PROMYELOCYTIC LEUKEMIA
APL corresponds to the M3 subtype of acute myeloge nous leukemia according to the French-American British (FAB) classification. It typically presents with a life-threatening hemorrhagic diathesis compatible with DIC. This is particularly common in the microgranular variant (M3v) characterized by marked hyperleuko cytosiS. 49 ,50 One laboratory feature distinguishing the coagulopathy of APL from DIC of other clinical con ditions is that the level of two coagulation inhibitors, antithrombin (AT) and protein C (PC), is often not de creased. The level of these proteins also correlates with the amount of hepatic dysfunction. Recently, some in vestigators have described increased level of annexin II-dependent fibrinolytic activity in APL myeloblasts. 51 In the APL leukemic NB4 cell line, this activity is re sponsive to treatment with ATRA. Both CP and TF have been identified in the NB4 cell line. The ATRA-induced APL differentiation in vitro is associated with the loss of capacity to express either CP or TF. [21] [22] [23] [24] APL subtype expresses the great est CP activity.52 In addition, the CP levels in the pa tients' bone marrow samples are related to the phase of disease, which is measurable at the onset but virtually absent during complete remission.5 3 Major determinants of coagulopathy of APL are factors associated with leukemic cells, including ~xpres sion of procoagulant activities (PCA), the expression of fibrinolytic and proteolytic properties, and the secretion of inflammatory cytokines, in other words, IL-1 (3 and TNFa. Leukemic blasts from patients with DIC secrete more of these factors. TNFa and IL-1 [3 induce expres sion of procoagulant TF, fibrinolysis inhibitor PAl -1, and surface adhesion molecules by endothelial cells. These cytokines also downregulate the expression of endothelial cell-derived thrombomodulin (TM). The TM-thrombin complex activates the PC system, which functions as a potent anticoagulant. TF upregulation and TM downregulation lead to a pro thrombotic con dition of the vascular wall. Leukemic promyelocytes contain both u-PA and tissue plasminogen activator (t-PA).54-57 In addition, granulocytic proteases such as elastase and chymotrypsin are found in the granules of myeloid blasts and are released into the bloodstream. These enzymes can interfere in several ways with the hemostatic system, that is, by degrading clotting factors in vitro and proteolysing fibrinolysis inhibitors. Elastase can also produce degradation of fibrinogen, producing a pattern of fibrin degradation products (FDP) different from that of plasmin.
Breast Cancer
Thromboembolism in cancer patients has been well studied in breast cancer. Ten studies concerning the in cidence and prevention of thrombotic disorders were listed by Levine 58 and involved 6844 patients with stage I to IV breast cancer undergoing chemotherapy. The incidence of thrombosis increased from 2.1% in stages 111I to 17.6 % in stage IV. Postmenopausal patients were found to have an elevated risk of developing throm bosis. The anticancer drugs used in these studies were adriamycin, cyclophosphamide, epirubicin, flourouracil, methotrexate, prednisone, and vincristine. :rvlitomycin was associated with thrombotic microangiopathic syn drome, which in most patients was a lethal event. 59 Sev eral authors documented that patients with operable, primary breast cancer, when receiving the cyclophos phamide, methotrexate, fluorouracil (CMF) regimen as an adjuvant chemotherapy,60,61 developed thrombosis in 2.2 to 6.8% of the cases, increasing to a risk of 17.6% in patients with metastatic breast cancer.62 Evaluation of coagulation factors through a 6-month period before and after the initiation of chemotherapy in the plasma of patients with stage II breast cancer revealed a signifi cant decrease in the PC and protein S antigen and ac tivity, whereas the PAI-llevels increased. 63 Chemotherapeutic drugs can alter endothelial ac tivity to platelets by inducing the release of IL-1, which in turn facilitates adhesion molecule expression on the endothelial cell surface. 64 This may contribute to the elevated risk of thrombus formation, In anticancer drug induced thrombosis, patients are observed to have de creased PCIAT ratio as well as increased endothelial reactivity. Other effects noted were release of TF from monocytes and endothelial cells and downregulation of thrombomodulin and a decreased fibrinolytic responseY Tamoxifen, a selective estrogen receptor modifier drug, has been used as the therapeutic agent of choice in patients with breast cancer in adjuvant setting and in metastatic disease, depending on the expression of hor monal receptors by the tumor. Tamoxiten has been asso ciated with substantially increased risk of thrombosis. In the long-term use of tamoxifen for a period of 5 years, the incidence of thrombosis was evaluated. 65 Of the patients treated with tamoxifen, 5,62% suffered venous thrombosis, whereas none was reported in the control group. Patients receiving tamoxifen have significantly lower activities of AT and PC compared with control subjects. Jankowski et al 66 reported that the no-antiplas min level was decreased and the levels of pl~sminogen were increased, whereas the AT and fibrinogen levels remained unchanged. Activated PC (APC) resistance related to F V Leiden mutation has been reported as a major cofactor for thrombosis in women receiving es trogen analogues. 6l1 The relative ratio of venous throm botic events in patients with current tamoxifen use is 7.1 as compared with control. The combination of che motherapeutic agents and tamoxifen significantly in crease venous and arterial thromboembolic events as compared with chemotherapy alone in premenopausal women.
Aromatase inhibitors are associated with lesser thromboembolic events. The recent finding of increased thrombogenicit), of apoptotic cells is relevant in such increased thromboembolic events. Apoptosis is induced by chemotherapeutic drugs, radiation, and hormones and is likely to be contributing to the thrombogenesis.
Tumor lysis Syndrome
Acute tumor lysis syndrome (ATLS) was formally rec ognized in 1980,67 giving a name to a hyperuricemic syndrome in the setting of lymphoid malignancies but now is recognized to be a specific oncological disorder that occurs when tumor cells are destroyed rapidly by natural means, chemotherapy, or radiation therapy. This syndrome is another example of increased thrombo genicity of apoptotic and necrotizing tumor cells. The classic laboratory tlndings include hyperuricemia, hy perkalemia, hyperphosphatemia, and hypocalcemia. The potassium and phosphate result from the intracel lular contents of dying cells; the uric acid results from the metabolism of purines in the degradation of nucleic acids; and the calcium is dOV'<llregulated in the presence of high phosphate levels. Renal failure results from tu bular precipitation of uric acid in acid pH and calcium phosphate in alkaline pH and classically shows evidence of calcification on renal ultrasound. 68 Clinically, the pa tient may have nausea, lethargy, clouding of the urine, renal colic, or, rarely, joint discomfort or cardiac ar rhythmias. Exacerbating factors include heavy tumor burden, high tumor growth fraction, dehydration, con current renal insufficiency, and initiation of rapidly ef fective therapies. including radiation therapy, cortico steroids, and cytotoxic chemotherapy. 69 The time of greatest risk of ATLS is during initiation of therapy,7o especially rapidly effective therapies such as induction therapy for acute lymphoblastic leukemia in children. It has been postulated that ATLS develops as a conse quence of the high rate of tumor cell death associated with aggressive therapy. The resultant release of cellular contents leads to profound metabolic abnormalities. It is therefore not surprising that this syndrome is most commonly associated with hematologic malignancies, including lymphoblastic leukemia, chronic lymphocytic leukemia, and chronic myelogenous leukemia, and clas sicallY'with Burkitt's lymphoma. The severe degree of thrombogenicity often leads to microvascular coagula tion and a DIC picture.
Modification in Management
Because the association of increased risk of thrombosis in malignant diseases is well-recognized, stress has been laid on the prophylaxis of deep vein thrombosis, espe cially in hospitalized patients. In light of the findings of increased thrombogenicity of tumor cells undergo ing apoptosis, prophylactic measures should be more aggressive, particularly during periods of increased apoptosis in the clinical course of cancer. These periods include those when the patient is receiving chemother apy, radiation therapy, hormonal therapy, and hema topoietic growth factors singly or in combination.
